Floatz logo

DROPERIDOL

Rectal Neoplasms

RenJi HospitalSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Rectal Neoplasms cohort.

Asset / SponsorPhaseRating
Eloxatin
Chongqing University Cancer Hospital
Phase 3BB
FLUOROURACILUM
Pei-Rong Ding
Phase 3BB
PROPOFOL
Uppsala University
Phase 4BB
Ertapenem
University of Ulm
Phase 4BB
Sevoflurane
Uppsala University
Phase 4BB

View all 44 →

Same molecule, other indications

DROPERIDOL is also rated in:

Postoperative Pain, AcuteDormant
BB
Indicative ·
65 / 100
View asset →
Postoperative Pain, ChronicDormant
BB
Indicative ·
65 / 100
View asset →
Systemic Inflammatory Response SyndromeDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →